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SUMMARY
Twenty -three patients with end-stage renal failure due to diabetic nephropathy
received renalreplacement treatment. Allpatients hadinsulin-dependent diabetes
mellitus. Nineteen transplants were performed in seventeen patients. Two-year
graft survival for all transplants was 74 % with a two -yearpatient survival post -
transplantation of81 %. Overall two-yearpatient survival was 73 %, compared
with 82 % in non -diabetic patients receiving renal replacement treatment. In
diabetic patients accepted for treatment there was a high incidence ofnon-renal
complications, particularly vascular disease. An aggressive approach to the
treatment of vascular disease in these patients may improve overall survival
rates.
INTRODUCTION
The diagnosis of diabetic nephropathy in an individual diabetic patient is usually
presumed in the presence of proteinuria and impaired renal function in
association with diabetic retinopathy. Hypertension is almost invariably present
at some stage and common histological features are diffuse and nodular
glomerulosclerosis. The nephropathy may be compounded by other diabetic
renal complications such as atheromatous renovascular disease, pyelonephritis,
papillary necrosis and neurogenic bladder.
The prevalence of diabetic nephropathy increases with the duration of diabetes to
a peak of around 20% after 20- 25 years.1 After 25 years the annual incidence
declines, indicating that the development of nephropathy is not solely dependent
on the duration of diabetes.2 Renal failure secondary to diabetic nephropathy was
responsible for over one quarter of the deaths in one study3 of patients in whom
insulin -dependent diabetes mellitus was diagnosed before 31 years of age. This
and other similar studies4 5 emphasised the need for more liberal extension of
renal replacement programmes to diabetic uraemic patients. The proportion of
new patients with end -stage renal failure due to diabetes mellitus referred for
renal replacement treatment is rising in Northern Ireland. To date, all patients
have had insulin-dependent (type 1) diabetes mellitus. In the United Kingdom
Renal Unit, Belfast City Hospital, Belfast, Northern Ireland, BT9 7AB.
A P Maxwell, MB, BCh, MRCP, Registrar.
J F Douglas, MA, BCL, MB, BCh, FRCP, Consultant Nephrologist.
C C Doherty, MD, MRCP, Consultant Nephrologist.
W E Nelson, MD, MRCP, Consultant Nephrologist.
R A Donaldson, BSc, MB, BCh, FRCS, Consultant Urologist.
Mary G McGeown, CBE, DSc(Hon), MD, PhD, FRCP, FRCPEd, FRCPI, Consultant Nephrologist,
Physician in Administrative Charge.
Correspondence to Dr Maxwell.
© The Ulster Medical Society, 1988.Diabetic nephropathy
overall, the proportion of diabetics with end-stage renal failure accepted for
treatment had risen to 1 1.1 % in 1984,6 a figure still well below those of 25% in
the USA7 (although more elderly non-insulin dependent diabetic patients are
treated there) and over 15 % in some European countries;6 this may reflect a
lower prevalence and/or under-referral of diabetic renal failure. In diabetic
patients with end-stage renal failure who receive renal transplants, the outcome
compares favourably with that of non -diabetic patients in some centres.8
However, sub-groups of diabetic patients with severe vascular disease have
shown a clear excess of graft failure and patient mortality.9
This paper outlines the experience of the Renal Unit at the Belfast City Hospital in
treating diabetic nephropathy between April 1979 and May 1987.
PATIENTS
Twenty-three patients (14 male, 9 female) were accepted for renal replacement
treatment. Their ages ranged from 23 to 62 years (mean 37.3) at time of referral.
Renal replacement treatment commenced at a mean age of 38.3 years. The
duration of diabetes ranged from 8 to 38 years (mean 21.7). Assessment for
renal replacement treatment was generally late in the progression of renal failure:
the mean serum creatinine was 773 pmol/l at referral, and mean creatinine
clearance 10 ml/min. Twenty-one percent of patients were referred as an
emergency with life-threatening illness including pulmonary oedema. Diabetic
nephropathy was a presumptive clinical diagnosis in all patients based on the
presence of diabetic retinopathy, heavy proteinuria and impaired renal function.
Nephrectomy and post -mortem pathological evidence confirmed the presence of
diabetic nephropathy with typical histological features of diffuse and nodular
glomerulosclerosis, arteriosclerotic lesions and interstitial fibrosis in all five cases
examined; atheromatous renovascular disease was present in addition in three of
these cases.
TABLE
Complications present at renal referral in 23 insulin -dependent diabetic patients
EYES Number
Retinopathy 23 100%
Proliferative retinopathy requiring laser therapy 16 70%
Blindness 5 22%
CARDIOVASCULAR
Abnormal ECG 18 78%
ECG criteria for myocardial infarction 7 30%
Hypertension (BP>150/90) 22 96%
Angina 5 20%
CEREBROVASCULAR
Previous stroke 2 9%
PERIPHERAL VASCULAR DISEASE
Intermittent claudication/ischaemia 8 34%
Amputation 2 8%
PERIPHERAL NEUROPATHY 13 57%
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There was a high prevalence of non -renal diabetic complications in patients at
the time of referral (Table). Retinopathy was present in all and 70% had received
laser photocoagulation for proliferative retinopathy; 22 % were registered blind.
Cardiovascular disease was common: ECG recordings were reviewed by one
investigator (APM) - 78% had an abnormal ECG, and 30% had the electro-
cardiographic criteria for a previous myocardial infarction. Angina pectoris was
present in 22 %, and hypertension (BP >150/90) in 96%. The prevalence of
cerebrovascular disease was lower, 9% having had a completed stroke while
carotid bruits were heard in 9%. Evidence of peripheral neuropathy was found in
57 % based on clinical symptoms and signs, and nerve conduction studies in
13% of these patients confirmed the clinical diagnosis. Peripheral vascular
disease had produced considerable morbidity in 34% of patients, and above-
knee amputations had been required in 8% (two cases). Three further patients
had above -knee amputations shortly after commencing renal replacement
treatment.
RENAL REPLACEMENT THERAPY
The mean age for commencing treatment was 38 years. Dialysis therapy was
started in 60% of patients for refractory pulmonary oedema or hypertension, and
in a further 30% for uraemic symptoms. Initial treatment was haemodialysis for
the majority (61 %), peritoneal dialysis in 30% and transplantation in 9%.
Haemodialysis. Fourteen patients initially started treatment with haemodialysis.
Three patients had been commenced on intermittent peritoneal dialysis and were
later changed to haemodialysis for reasons of infection and availability. Two
patients changed from haemodialysis to chronic ambulatory peritoneal dialysis
following assessment of chest pain. Both patients underwent coronary artery
bypass grafting for multi -vessel coronary artery disease and were managed post -
operatively by peritoneal dialysis. Vascular access has proved difficult in several
patients.
Intermittent peritoneal dialysis. Five patients began intermittent peritoneal
dialysis: one was subsequently transplanted, one was trained for chronic
ambulatory peritoneal dialysis and three patients were transferred to
haemodialysis.
Chronic ambulatory peritoneal dialysis. Two patients started this as their initial
treatment and three are currently maintained on this mode of dialysis. Two of
these patients manage the technique successfully despite being registered blind.
Transplantation. Nineteen renal transplants have been performed on 17
patients. Eighteen transplants were cadaver grafts, and one patient received a
graft from a living related donorwhich neverfunctioned becauseofintra-operative
hypotension. The mean duration of dialysis pre-transplant was 9.9 months.
Thirteen patients survive (11 with functioning grafts and two having returned to
dialysis). Two-year graft survival is 74% including one operative death and two
cases of primary non-function due to graft artery thrombosis. Comparable results
in this unit for two-year graft survival in non-diabetics was 81%, and two-year
patient survival 82 %.
Operative problems encountered included atheromatous pelvic vessels in five
recipients, in one case necessitating formal revascularisation at the time of
transplant. Wound infections occurred in 38% post-operatively. Early transplant
rejection (within three months) occurred in 10 grafts and required treatment with
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high dose oral prednisolone. In three cases plasma exchange was included in the
management of rejection. Eight of the 10 grafts continued to function. Diabetic
transplant recipients were treated with a combination of low dose prednisolone
(20 mg daily reduced in stages over 18 months to 10 mg daily) and azathioprine
(3mg/kg).
Mortality. Seventeen of the 23 patients accepted for treatment survived to
May 1987. Four transplant recipients died and post mortem examinations
were obtained in three cases. One patient died from a combination of bacterial
infection and transplant rejection; the other two suffered myocardial infarctions.
The fourth transplant patient died suddenly at home after recent onset of atrial
fibrillation, presumably also on the basis of ischaemic heart disease. The two
deaths in non-transplanted patients occurred during haemodialysis, one from
a myocardial infarction (confirmed by post-mortem examination revealing
extensive triple vessel coronary artery disease which had been clinically silent),
the other due to a cerebrovascular accident. Overall the two -year patient survival
for all modalities of treatment during the period studied was 73.5%.
DISCUSSION
In Northern Ireland the incidence of new cases of diabetic renal failure has been
estimated at 7.6 cases/million/year, which is lower than in other UK regions
reported.10 The number of patients who have received treatment to date is less
than the estimated number for a variety of reasons including limited resources
and under-referral. The absence of older patients with non-insulin -dependent
diabetes mellitus in our treatment group probably represents under-referral of
such patients because of perceived bias towards treatment of younger patients
with end-stage renal failure - a policy initially reflecting medical opinion I I but
latterly reflecting constraints on the expansion of the renal failure service. From
1979 the rate of referral of patients with diabetic nephropathy to the Renal Unit
has been rising, and many insulin-dependent and non-insulin-dependent diabetic
patients will reach the renal replacement programme this year. In view of
the expected increase in the number of diabetic patients for assessment we
have reviewed our preliminary experience in treatment of end-stage diabetic
nephropathy.
The diabetic patients reported in this paper represent 7.3% ofthe total number of
new patients accepted for renal replacement therapy in Northern Ireland between
1979 and 1987. However, over the last two years (June 1985 to May 1987),
diabetic patients accounted for 12% ofthe total treated, indicating that increasing
numbers of diabetic patients are receiving renal replacement therapy. Some
diabetic patients who were referred in the period reported were not treated for
reasons of advanced age, dependency and overwhelming medical complications.
These criteria were equally applied to non-diabetic patients referred for assess-
ment and reflect earlier restrictions on the provision of care for patients with renal
failure. The number of diabetic patients with renal impairment in Northern Ireland
is unknown as the recent survey '0 only selected for study diabetics with advanced
renal failure (serum creatinine >500 pmol/l and urea >25 mmol/l). Most ofthe
patients reported here were referred at a late stage of their renal disease and
required renal replacement, on average, within a year. Pulmonary oedema and
hypertension were the main indications for starting treatment. A high incidence
of non -renal diabetic complications was evident which posed many management
problems. While vascular disease did not prove a contraindication to renal
replacement treatment, our experience suggests that an aggressive approach to
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this frequently co -existing problem is essential. Myocardial infarction was
implicated in 50% of the deaths in diabetic patients in the period reported.
Significant ischaemic heart disease may be present 12 without symptoms, often
declaring itself only after treatment for end -stage renal failure has commenced.
Two patients with multi-vessel coronary artery disease, which became sympto-
matic on haemodialysis treatment, underwent coronary artery bypass grafting
procedures. These patients were managed post-operatively by peritoneal dialysis
and later trained for continuous ambulatory peritoneal dialysis. Some centres
have recommended coronary artery angiography as a routine pre-transplant
screening procedure in diabetic uraemic patients 13 and others have reported
that diabetic patients with significant coronary artery disease had a worse
prognosis for all modalities of treatment but a trend to better survival following
transplantation.'4 In those patients with significant peripheral vascular disease
transplantation may worsen lower limb ischaemic by a 'vascular steal'
phenomenon resulting in amputation in some cases shortly after a transplant
procedure. Rimmer and colleagues9 found higher mortality and graft loss
following transplantation in patients with pre-existing atherosclerotic vascular
disease and concluded this should influence the choice between therapeutic
alternatives in diabetics with end-stage renal failure. Revascularisation procedures
might favourably alter the survival characteristics of this group following trans-
plantation. The vascular disease may lead to difficulty with vascular access."
Other problems encountered include autonomic neuropathy (urinary retention,
hypotension), gastrointestinal symptoms and a wasting syndrome.'5 The two-
year graft survival of 74% and two year patient survival of 81 % post transplant-
ation must in this series be interpreted with caution in view of the relatively small
numbers of patients involved and the relatively short period of follow -up.
Diabetic transplant recipients were treated with conventional immunosuppressive
therapy (azathioprine and low dose prednisolone) and it is still our policy to
reserve cyclosporin therapy for patients (diabetic or non -diabetic) who are
intolerant of azathioprine.
The treatment of diabetic patients with end-stage renal failure by dialysis 16, 17
and transplantation8 improves patient survival. The cost of renal replacement
treatment for diabetic patients is higher than that for non -diabetic patients, one
estimate suggesting transplantation is one-third more expensive.'8 New patients
with end -stage renal failure due to diabetic nephropathy are now forming an
increasing proportion of the numbers accepted for treatment in the United
Kingdom,6 and concern has been expressed that many patients who could benefit
from treatment are probably not receiving it.'19 20 The survey of diabetic renal
failure for 1985 conducted by the Joint Working Party of the Renal Association,
the British Diabetic Association and the Royal College of Physicians concluded
that up to 40% of patients suitable for treatment were not receiving it.10
While prevention of diabetic nephropathy remains the ultimate goal, current aims
are earlier referral and joint management of the patient by nephrologists and
diabetologists, with stricter blood pressure21' 22, 23 and metabolic control 24
attempting to reduce the rate of progression of diabetic nephropathy. End-stage
renal failure in diabetic uraemic patients can be managed successfully with a
combination of dialysis and transplantation. Vascular disease, whilst an important
factor determining eventual outcome, has not proved a contraindication to
treatment. The quality of life for the individual must also be considered in
choosing between therapeutic alternatives in renal replacement treatment for
diabetic patients.
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Royal Victoria Hospital
FRIENDS OF THE ROYAL
The formation of a 'Friends of the Royal' group is currently under way. In
order to explain the aims and object of the Friends and elect a Committee,
an inaugural meeting is being held at 3.30 pm on Wednesday, 15 June,
1988 in Bostock House Ballroom, RVH. It is hoped that this organisation
will promote thework ofthe Royal through the Ladies Committee, Working
Mens Committee and Ex-Patients Guild and will in addition take on other
projects to assist the Hospital. Anyone interested in our endeavours is
welcome at this meeting. We look forward to your support and ideas.
Ingrid Allen
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